STI News: CDC To Issue New Guidelines Advocating The Usage Of The Antibiotic Doxyclycline After Sex To Prevent STIs Like Syphilis, Chlamydia And Gonorrhea
: In response to the escalating rates of sexually transmitted infections (STIs) across the United States, the U.S. Centers for Disease Control and Prevention (CDC) is set to release groundbreaking guidelines recommending the use of the antibiotic doxycycline after sexual encounters. This innovative approach comes amid alarming increases in syphilis and gonorrhea cases, signaling a pressing need for novel preventive measures.
The resurgence of syphilis, particularly among pregnant women and men who have sex with men, has emerged as a significant public health threat. According to Dr Christopher Foltz, an infectious disease specialist at Cedars-Sinai in Los Angeles, syphilis cases among gay and bisexual men increased by 7% between 2020 and 2021. The rates among women saw a staggering 55.3% jump from 2020 to 2021, with a cumulative rise of 217.4% between 2017 and 2021. These trends have prompted health experts to explore innovative strategies to curb the spread of STIs, especially in high-risk populations.
To address this growing crisis, the U.S. CDC is proposing the use of doxycycline as a preventive measure for bacterial STIs. This antibiotic, traditionally employed to treat conditions such as acne and pneumonia, has shown promise in recent clinical trials. A single 200-milligram dose taken within 72 hours of a sexual encounter was found to be effective in preventing syphilis and chlamydia infections.
The "Doxy on Demand" strategy is not intended to replace condom use but is seen as an additional layer of protection, especially for those who may not consistently use condoms during sexual activity. Dr Foltz emphasizes the importance of condom use to prevent other STDs and HIV. While the doxycycline approach is promising, it is not recommended for pregnant women or individuals allergic to tetracyclines, a class of antibiotics.
The CDC's proposed guidelines specifically target high-risk groups, including men who have sex with men and transgender women. The finalized guidance is expected to be released after public comments close on November 16. Health experts stress the urgency of implementing new preventive approaches, given the significant increase in STI cases since 2014.
According to past local STI News
coverages, the rising rates of gonorrhea, chlamydia, and syphilis in the U.S., with over 2.5 million reported cases in 2021 alone, highlight the need for innovative solutions in STI prevention.
A recent study involving 501 sexually active men demonstrated a 65% effectiveness of doxycycline in
reducing the incidence of these infections when taken within 72 hours after unprotected sex. The "emergency act" of proposing doxycycline post-exposure prophylaxis aims to address the ongoing STI epidemic.
Doxycycline, a broad-spectrum antibiotic belonging to the tetracycline family, has been a staple in treating various infections, including Lyme disease and acne. Concerns about antibiotic resistance are acknowledged, but experts argue that the benefits of using doxycycline for STI prevention outweigh the risks, especially given the urgency of the situation. Antibiotic resistance remains a significant public health issue, with over 2.8 million antimicrobial-resistant infections occurring in the U.S. each year, according to the CDC.
While the current recommendations focus on men who have sex with men and transgender women, ongoing research aims to explore the effectiveness of doxycycline post-exposure prophylaxis for cisgender women and transgender men. Dr John A. Nelson, an STI screening researcher, emphasizes the need for additional studies to determine the viability of this strategy for individuals with vaginas and cervixes.
As the CDC moves toward finalizing its guidance, the proposed use of doxycycline as a preventive measure highlights the need for innovative solutions to curb the escalating rates of STIs in the United States. The potential for "Doxy on Demand" to reduce the overall number of new infections offers hope in the fight against the STI epidemic, encouraging individuals to engage in open discussions with their healthcare providers about the best strategies for their individual risk levels.
The need for STI prevention in the United States is underscored by a clear and consistent increase in cases of the most common bacterial STIs, including gonorrhea, chlamydia, and syphilis, since 2014. Dr John A. Nelson, PhD, an STI screening researcher and director of the AIDS Education and Training Center at the Rutgers School of Nursing, emphasizes the severity of the issue, stating that "it's definitely a national problem." Over 2.5 million cases of chlamydia, gonorrhea, and syphilis were reported in 2021 alone, with syphilis cases witnessing a particularly alarming surge. America is not the only country in the world facing a STI crisis. In fact, it is believed that the crisis is more rampant and worrisome in the United Kingdom with other European countries such as Spain, Germany and Romania also trailing behind. In the United Kingdom, not only are STIs like gonorrhea, chlamydia, and syphilis at exponential levels but other even rare STIs like Lymphogranuloma venereum (LGV) and even Donovanosis are gaining prevalence. HIV rates are also on an increase in the United Kingdom due to reckless and unhygienic behaviors of the locals.
Infectious disease expert Dr David Goodman, MD, from UCLA Health, underscores the significance of early treatment, stating that "if you get medication onboard early enough after a sexual encounter, you treat that infection very early and can avoid complications of those infections."
However, concerns about antibiotic resistance persist. Greg Marks, PharmD, coordinator of the Antimicrobial Stewardship program at Cedars-Sinai Medical Center, acknowledges the potential risks associated with increased antibiotic use, citing the ability of bacteria to develop resistance over time. Antibiotic resistance is a pressing public health concern, with high volumes of antimicrobial-resistant infections occurring in the U.S. each year, according to the CDC. Such infections can lead to organ failure, extended recovery times, and, in severe cases, death.
Despite these concerns, health experts argue that the benefits of using doxycycline for STI prevention outweigh the risks. The urgency of the situation, with the ongoing STI epidemic, necessitates innovative and timely solutions. The proposed use of doxycycline, known as "Doxy on Demand" or "Doxy PEP" (post-exposure prophylaxis), offers a potential tool to curb the spread of STIs, particularly among high-risk populations.
For the latest STI News
, keep on logging to Thailand Medical News.